Zosano Pharma Corp

NASDAQ:ZSAN   12:33:23 PM EDT
0.61
0.00 (+0.53%)
Products

Zosano Pharma Granted Type C Meeting With FDA Regarding NDA Resubmission For M207 Following Preliminary Top-Line Pharmacokinetic Study Results

Published: 10/04/2021 12:32 GMT
Zosano Pharma Corp (ZSAN) - Zosano Pharma Granted Type C Meeting With FDA Regarding NDA Resubmission for M207 Following Preliminary Top-line Pharmacokinetic Study Results.
Zosano Pharma Corp - Until Co Resubmits NDA, Potentially Gets FDA Approval, Co is Unable to Estimate a Timeframe for Product Launch Or Revenue for 2022.